(Q44111064)

29 November 2017

title

Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate (English)

1 reference

29 November 2017

Rudolph G

1

1 reference

29 November 2017

Kloeters-Plachky P

series ordinal

2

1 reference

29 November 2017

Sauer P

series ordinal

3

1 reference

29 November 2017

Stiehl A

series ordinal

4

1 reference

29 November 2017

language of work or name

1 reference

1 August 2002

1 reference

European Journal of Clinical Investigation

29 November 2017

published in

1 reference

29 November 2017

volume

32

1 reference

29 November 2017

issue

8

1 reference

29 November 2017

page(s)

575-580

1 reference

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

GUDC inhibits cytochrome c release from human cholangiocyte mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Induction of sodium-dependent bile acid transporter messenger RNA, protein, and activity in rat ileum by cholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.2002.01030.X

10.1046/J.1365-2362.2002.01030.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference